DNM1P49: A Potential Drug Target and Biomarker (G730058)

Target Name: DNM1P49

NCBI ID: G730058

DNM1P49

Other Name(s): DNM1DN8@ | DNM1 pseudogene 49 | dynamin 1 pseudogene 49

DNM1P49: A Potential Drug Target and Biomarker

Introduction

Drug resistance is a major healthcare problem that has affected millions of patients worldwide. The development of new drugs and drug targets is a continuous process to overcome this problem. One of the potential drug targets is DNM1P49, which is a protein that is expressed in various tissues and cells of the body. In this article, we will discuss DNM1P49 as a drug target and biomarker.

DNM1P49: Structure and Function

DNM1P49 is a 14kDa protein that is expressed in various tissues and cells of the body. It is a member of the DNM1 family of proteins, which are involved in the regulation of DNA replication and repair. DNM1P49 is a unique protein that is expressed in the nuclei of epithelial and mesenchymal tissues, including breast epithelial cells, lung fibroblasts, and human tissue culture models.

DNM1P49 plays a critical role in the regulation of cell cycle progression and the association with the maintenance of stem cell properties. It is involved in the regulation of the G1/S transition, which is the first step in cell cycle progression from G0 to S. DNM1P49 has been shown to play a role in the regulation of cell proliferation and differentiation, as well as in the regulation of cell survival.

DNM1P49 is also involved in the regulation of apoptosis, which is a critical mechanism of cell death that is regulated by various factors, including DNM1P49. DNM1P49 has been shown to play a role in the regulation of apoptosis in various tissues and cells, including cancer cells.

DNM1P49 as a Drug Target

DNM1P49 is a potential drug target due to its involvement in various cellular processes that are crucial for cancer development. One of the potential mechanisms by which DNM1P49 can be targeted is through its role in the regulation of cell proliferation and apoptosis.

DNM1P49 has been shown to promote the growth and survival of various cancer cells, including breast, lung, and ovarian cancer cells. This is because DNM1P49 can inhibit the negative effects of the growth factor PDGF-A, which is a critical factor for cancer cells growth and survival.

In addition, DNM1P49 has also been shown to promote the development of cancer by inhibiting the negative effects of the inhibitor protein p53. p53 is a critical protein that is involved in the regulation of apoptosis, and its inhibition can lead to the survival of cancer cells.

Another potential mechanism by which DNM1P49 can be targeted is through its role in the regulation of cell differentiation. DNM1P49 has been shown to play a role in the regulation of stem cell properties and the association with the stem cell-progeny balance.

DNM1P49 has been shown to promote the self-renewal and maintenance of stem cells, as well as the ability of stem cells to differentiate into various cell types. This is because DNM1P49 is involved in the regulation of the stem cell-progeny balance, which is critical for the development and maintenance of stem cells.

DNM1P49 as a Biomarker

DNM1P49 has also been shown to be a potential biomarker for various diseases, including cancer. One of the potential mechanisms by which DNM1P49 can be used as a biomarker is through its involvement in the regulation of cell apoptosis.

Studies have shown that DNM1P49 is involved in the regulation of apoptosis in various tissues and cells, including cancer cells. This is because DNM1P49 is involved in the negative regulation of

Protein Name: Dynamin 1 Pseudogene 49

The "DNM1P49 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DNM1P49 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets